Call for full disclosure on drug data
Drug companies should be forced to publish all their trial data rather than selecting evidence to back up their claims, experts said.
A review of clinical trial results for the anti-depressant Edronax showed pharmaceutical firms did not publish most of the data for the drug.
The review found the drug was "ineffective and potentially harmful". It is available in the UK and several other European countries but has been rejected for use in the US.
Experts in the British Medical Journal found 13 treatment trials on just over 4,000 patients were carried out using the drug but data on 74 per cent of patients remained unpublished.